ERNA

4 - Ernexa Therapeutics Inc. (0000748592) (Issuer)

4 - Ernexa Therapeutics Inc. (0000748592) (Issuer)

4 - Ernexa Therapeutics Inc. (0000748592) (Issuer)

4 - Ernexa Therapeutics Inc. (0000748592) (Issuer)

4 - Ernexa Therapeutics Inc. (0000748592) (Issuer)

4 - Ernexa Therapeutics Inc. (0000748592) (Issuer)

3 - Ernexa Therapeutics Inc. (0000748592) (Issuer)

Nine CEOs. Nine investment stories. 60 seconds each to answer the question that matters most to investors: Why now?On-demand video series gives investors rapid access to company leadership, recent milestones, upcoming catalysts and the opportunities management believes investors should be watching todayAccess on demand conference here FRENCHTOWN, NJ / ACCESS Newswire / August 27, 2026 / JTC Team ("JTC"), a fully integrated corporate communications and investor relations firm, today announced the release of its Virtual Investor "Why Now" On-Demand Conference, featuring a fast-paced series of 60-second presentations from the CEOs of nine publicly traded companies.The premise is simple: Why sho

Video webcast now available here CAMBRIDGE, Mass., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (NASDAQ:ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced that it participated in the Virtual Investor "Why Now" on-demand conference. During the webcast, Sanjeev Luther, President and Chief Executive Officer of Ernexa Therapeutics, presented the Company’s investment thesis and highlighted why he believes now is a pivotal time for Ernexa. The pitch discusses the Company’s planned transition into a clinical-stage biotechnology company, with lead candidate ERNA-101 advancing toward a planned Investig

Seasoned biotechnology founder, public company CFO and corporate strategist brings more than 25 years of leadership in oncology, capital markets, M&A and corporate governance  Appointment further strengthens leadership team at a pivotal inflection point as Company positions ERNA-101 for planned IND submission in Q3 2026 and Phase 1 clinical study initiation in the Q4 2026 CAMBRIDGE, Mass., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (NASDAQ:ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced the appointment of David Polinsky to its Board of Directors, further strengthening the Company's leader

10-Q - Ernexa Therapeutics Inc. (0000748592) (Filer)

CEO Discusses Why the Future of Cancer Treatment May Belong to Combination Approaches and How ERNA-101 Was Designed to Turn Immunologically "Cold" Tumors Into Targets for the Immune System Video Showcases Differentiated Off-the-Shelf Cell Therapy Platform, Independent Validation of Complete Tumor Clearance in Preclinical Studies and Continued Execution Toward Planned IND Submission in Q3 2026 Access the Ernexa CEO Corner here  CAMBRIDGE, Mass., July 24, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (NASDAQ:ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today released a new installment of its CEO Corner series fea

DENVER, July 15, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) – Today’s announcements from NeOnc Technologies (NASDAQ:NTHI), Ernexa Therapeutics (NASDAQ:ERNA), and VivoSim Labs (NASDAQ:VIVS) highlight three distinct pathways to potential value creation. NeOnc Technologies NeOnc Technologies (NASDAQ:NTHI) announced that it has received written feedback from the U.S. Food and Drug Administration regarding the chemistry, manufacturing, and controls (CMC) development program for its lead drug candidate, NEO212, a novel temozolomide-perillyl alcohol conjugate being developed for malignant brain tumors and other central nervous system cancers. Rather than proceeding with its scheduled Type B

Independent CRO Successfully Reproduces ERNA-101 Combination Data in Larger Preclinical Study, Significantly Strengthening Confidence as Company Advances Toward IND  ERNA-101 Plus Anti-PD-1 Achieved Complete Tumor Clearance and Long-Term Survival in Two-Thirds of Treated Animals While No Complete Responses Were Observed in Any Monotherapy or Control Group IND Submission Planned for Q3 2026 with First-in-Human Phase 1 Trial Expected to Begin in Q4 2026 CAMBRIDGE, Mass., July 15, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (NASDAQ:ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced compelling new precli

CEO discusses ERNA-101's potential to transform immunologically "cold" tumors into tumors the immune system can recognize and kill Video highlights compelling preclinical data, differentiated off-the-shelf iMSC platform and progress toward planned first-in-human clinical evaluation IND submission planned for the third quarter of 2026 with first-in-human Phase 1 study anticipated to begin in the fourth quarter of 2026 Access the Ernexa CEO Corner here CAMBRIDGE, Mass., July 14, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (NASDAQ:ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today released a new installment of

8-K - Ernexa Therapeutics Inc. (0000748592) (Filer)

8-K - Ernexa Therapeutics Inc. (0000748592) (Filer)

8-K - Ernexa Therapeutics Inc. (0000748592) (Filer)

New platform provides additional perspective on Ernexa's mission to deliver hope for patients through innovative, scalable cell therapies while improving accessibility and affordability Inaugural video highlights Company's mission to provide hope, scientific strategy and commitment to advancing differentiated cell therapies Access the Ernexa CEO Corner here CAMBRIDGE, Mass., June 25, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (NASDAQ:ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today launched its CEO Corner platform featuring Sanjeev Luther, President and Chief Executive Officer of Ernexa Therapeutics. The CE

CAMBRIDGE, Mass., June 17, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (NASDAQ:ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today highlighted significant progress across manufacturing, regulatory and clinical development activities supporting ERNA-101, the Company's lead oncology candidate. With manufacturing process development completed, GMP production underway, IND-enabling activities advancing and an Investigational New Drug (IND) submission planned for the third quarter of 2026, Ernexa believes it is well-positioned to initiate its first-in-human Phase 1 clinical study in the fourth quarter of 2026 and tran

Access the segment here CAMBRIDGE, Mass., June 09, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (NASDAQ:ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced the participation in a Virtual Investor KOL Connect segment featuring Ira S. Winer, MD, PhD, FACOG, Scientific Advisory Board Member at Ernexa Therapeutics, Professor in the Division of Gynecologic Oncology at Wayne State University School of Medicine and gynecologic oncologist at the Barbara Ann Karmanos Cancer Institute. During the discussion, Dr. Winer provided perspective on the significant unmet need that continues to exist in ovarian cancer, li

CAMBRIDGE, Mass., May 27, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (NASDAQ:ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced significant progress in the development of ERNA-101, the company's lead therapeutic candidate, achieving multiple critical milestones that position the program for a planned Investigational New Drug (IND) submission in the third quarter of 2026 and the anticipated initiation of its first-in-human clinical study. The company has successfully completed process development activities for the ERNA-101 manufacturing process and has now transitioned into Good Manufacturing Practice

Discussion highlights significant unmet need in ovarian cancer and the potential of ERNA-101 to address limitations of current therapies Segment also discusses evolving treatment landscape, immunologically "cold" tumors and the future potential of off-the-shelf cell therapy approaches Access the segment here CAMBRIDGE, Mass., May 20, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (NASDAQ:ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced the release of a Virtual Investor KOL Connect segment featuring Dr. Elena Ratner, Professor in the Department of Obstetrics, Gynecology and Reproductive Sciences at Yal

SCHEDULE 13G/A - Ernexa Therapeutics Inc. (0000748592) (Subject)

DEFA14A - Ernexa Therapeutics Inc. (0000748592) (Filer)